Mills, K
Dual-agonist compounds such as Tirzepatide add GIP receptor activity on top of the GLP-1 pathway, producing a more pronounced metabolic effect than single-agonist compounds but still without the glucagon-receptor-driven energy expenditure component unique to triple agonists
rn Bileimi: Aqua, Propanediol, Caffeine, Glycerin, Niacinamide, C12-13 Pareth-9,Panthenol, 1,2-Hexanediol, Caprylyl Glycol,3-O-Ethyl Ascorbic Acid, Hydroxyethylcellulose, Glutathione, Sodium Hyaluronate, PotassiumSorbate, Propyl Gallate, Gallyl Glucoside, Epigallocatechin Gallatyl Glucoside, BenzylAlcohol, Dehydroacetic Acid
In patients with pathological cardiac remodeling, cardiac lipid oxidation and the TCA cycle are inhibited, glycolysis is enhanced but glucose oxidation is unchanged or reduced, and the lack of energy supply further leads to HF 13,30